Literature DB >> 8592680

Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes.

M Ishigami1, T Tokui, T Komai, K Tsukahara, M Yamazaki, Y Sugiyama.   

Abstract

PURPOSE: We have already demonstrated that the HMG-CoA reductase inhibitor, pravastatin is actively taken up by isolated rat hepatocytes via a multispecific anion transporter (Yamazaki et al., Am. J. Physiol. 264, G36-44, (1993)). We further attempted the quantitative evaluation of this uptake in different experimental systems.
METHODS: We have quantified the initial uptake of pravastatin by both primary cultured hepatocytes and by isolated perfused rat liver using the multiple indicator dilution (MID) method.
RESULTS: The permeability surface area product for the influx (PSinf) of pravastatin evaluated in MID study was comparable with those reported previously in isolated rat hepatocytes and in vivo. Furthermore, the highly concentrative uptake (influx clearance >> efflux clearance) of pravastatin was confirmed by kinetic analysis of the dilution curves obtained in the MID study. On the other hand, the uptake by primary cultured cells was significantly lower than that by isolated cells, and the ability of hepatocytes to take up pravastatin showed a decrease with time in culture (0-96 hr). The Vmax for uptake diminished with increasing time in culture, while no significant change was observed in both Km and nonspecific diffusion clearance.
CONCLUSIONS: The MID method in isolated perfused liver which maintains the spatial and anatomical architecture can be used to quantitatively evaluate the initial uptake of pravastatin. Furthermore, the ability of hepatocytes to take up pravastatin is diminished in culture with time and this is caused by a decrease in Vmax.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592680     DOI: 10.1023/a:1016226024587

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Capillary exchange modeling. Barrier-limited and flow-limited distribution.

Authors:  C A Goresky; W H Ziegler; G G Bach
Journal:  Circ Res       Date:  1970-11       Impact factor: 17.367

2.  A new method for assessment of drug disposition in muscle: application of statistical moment theory to local perfusion systems.

Authors:  T Kakutani; K Yamaoka; M Hashida; H Sezaki
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

3.  Isolation and use of liver cells.

Authors:  P Moldéus; J Högberg; S Orrenius
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

4.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

5.  Regulation of amino acid transport systems by amino acid depletion and supplementation in monolayer cultures of rat hepatocytes.

Authors:  D S Kelley; V R Potter
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

6.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

7.  Role of ligandin in transfer of bilirubin from plasma into liver.

Authors:  A W Wolkoff; C A Goresky; J Sellin; Z Gatmaitan; I M Arias
Journal:  Am J Physiol       Date:  1979-06

8.  Effect of albumin on hepatic uptake of warfarin in normal and analbuminemic mutant rats: analysis by multiple indicator dilution method.

Authors:  S C Tsao; Y Sugiyama; Y Sawada; S Nagase; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

9.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

Authors:  M Yamazaki; H Suzuki; M Hanano; T Tokui; T Komai; Y Sugiyama
Journal:  Am J Physiol       Date:  1993-01

10.  Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system.

Authors:  H Nakamura; H Sano; M Yamazaki; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1994-06       Impact factor: 4.030

View more
  12 in total

1.  Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  J Pharmacol Exp Ther       Date:  2011-12-21       Impact factor: 4.030

2.  Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats.

Authors:  M Yamazaki; S Akiyama; R Nishigaki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

3.  Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.

Authors:  Yoshihisa Shitara; Daisuke Sugiyama; Hiroyuki Kusuhara; Yukio Kato; Takaaki Abe; Peter J Meier; Tomoo Itoh; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

4.  Pharmacokinetic study of the hepatobiliary transport of indomethacin.

Authors:  H Kouzuki; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

5.  Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.

Authors:  T Tokui; D Nakai; R Nakagomi; H Yawo; T Abe; Y Sugiyama
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

6.  Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions.

Authors:  M Ishigam; M Uchiyama; T Kondo; H Iwabuchi; S Inoue; W Takasaki; T Ikeda; T Komai; K Ito; Y Sugiyama
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

Review 7.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

8.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

Review 9.  Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.

Authors:  M Yamazaki; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

10.  Effects of High-cholesterol Diet on Pravastatin Disposition in the Perfused Rat Liver.

Authors:  Atsushi Kawase; Ayumi Handa; Masahiro Iwaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.